» Articles » PMID: 17690103

Determination of Dual Effects of Parathyroid Hormone on Skeletal Gene Expression in Vivo by Microarray and Network Analysis

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2007 Aug 11
PMID 17690103
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Parathyroid hormone (PTH) stimulates bone formation when injected daily but causes severe bone loss with continuous infusion. The mechanism of its paradoxical effects is still elusive. In this study, we compared changes in the gene expression profile in bone induced by intermittent or continuous treatment with three different PTH peptides, PTH-(1-34), -(1-31), and -(3-34), in Sprague-Dawley female rats. PTH-(1-34) regulated numerous genes (approximately 1,000), but differentially, in both regimes. PTH-(1-31) regulated a similar number of genes in the intermittent regimen but fewer in the continuous regimen, consistent with its less potent catabolic effect. PTH-(3-34) regulated very few genes in both regimes, which suggests the protein kinase C pathway plays a limited role in mediating the dual effects of PTH, whereas the cAMP-dependent protein kinase A pathway appears to predominate. In the intermittent treatment, many genes encoding signaling mediators, transcription factors, cytokines, and proteases/protease inhibitors are regulated rapidly and cyclically with each PTH injection; genes associated with skeletal development show a slowly accruing pattern of expression. With continuous treatment, some genes are regulated from 6 h, and the mRNA levels are sustained with a longer infusion, whereas others show a kinetic decrease and then increase later. Significant up-regulation of genes stimulating osteoclastogenesis in the anabolic regime suggests a provocative and paradoxical theme for the anabolic effect of PTH that a full anabolic response requires a transient up-regulation of genes classically associated with a resorptive response. Ingenuity pathway analysis was performed on the microarray data. A novel signaling network was established that is differentially regulated in the two PTH treatment regimes. Key regulators are suggested to be AREG, CCL2, WNT4, and cAMP-responsive element modulator.

Citing Articles

Unlocking the mysteries of n-oxPTH: implications for CKD patients.

Zhang L, Cao H Front Endocrinol (Lausanne). 2025; 15():1455783.

PMID: 39829956 PMC: 11738944. DOI: 10.3389/fendo.2024.1455783.


Sexual dimorphism of MASLD-driven bone loss.

Goldscheitter G, Seneshaw M, Mirshahi F, Buettmann E, Genetos D, Sanyal A bioRxiv. 2024; .

PMID: 39651131 PMC: 11623524. DOI: 10.1101/2024.11.25.625246.


Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.

Iwanowska M, Kochman M, Szatko A, Zgliczynski W, Glinicki P Int J Mol Sci. 2024; 25(21).

PMID: 39519190 PMC: 11546563. DOI: 10.3390/ijms252111639.


The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34).

Yee C, Meliadis C, Kaya S, Chang W, Alliston T Front Endocrinol (Lausanne). 2024; 15:1342938.

PMID: 39092287 PMC: 11291448. DOI: 10.3389/fendo.2024.1342938.


The Molecular Mechanisms Underlying the Systemic Effects Mediated by Parathormone in the Context of Chronic Kidney Disease.

Maranduca M, Cozma C, Clim A, Pinzariu A, Tudorancea I, Popa I Curr Issues Mol Biol. 2024; 46(5):3877-3905.

PMID: 38785509 PMC: 11120161. DOI: 10.3390/cimb46050241.